U16 / Central South University, Shanghai Unicar - LARVOL DELTA

Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells) (ASH 2024) - P=N/A | "CD20 CAR-T was administered at a target dose of 1.0×107 CAR-T cells/kg after a 3-day conditioning chemotherapy with fludarabine and cyclophosphamide. Conclusion : Long-term follow-up demonstrated that CD20 CAR-T therapy can produce a deep and durable response with a favorable safety profile in patients with rituximab-refractory/relapsed B-NHL. Notably, patients who had received rituximab within 3 months had a poorer prognosis."

CAR T-Cell Therapy • Clinical • Anemia • B Cell Non-Hodgkin Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • CD20

Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

New P1/2 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • IL6

Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphoma. (PubMed, Discov Oncol) - "The effective dose of CAR-T20 in mice starts from 1 × 10 per mouse, equivalent to a clinical dose of 5 × 10/kg. Together, our data support the clinical translation of CAR-T20 for R/R B-cell NHL patients."

CAR T-Cell Therapy • Journal • Preclinical • Burkitt Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20 • IFNG • IL10 • IL2 • IL6

CD20-Specific Chimeric Antigen Receptor-Expressing T Cells As Salvage Therapy in Rituximab-Refractory CD20(+) B-Cell Non-Hodgkin Lymphoma (ASH 2021) - "In conclusion，these findings suggest that the use of CAR T-20 can be served as a salvage therapy in Rituximab-refractory CD20(+) B-cell Non-Hodgkin Lymphoma and raises the possibility of using CAR T-20 in an early disease stage."

Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20 • FDG PET